Rasburicase dose optimization for tumor lysis syndrome management in a network of community oncology practices.
Steven GilmoreMelissa CarrollElizabeth KoselkeShannon M HoughPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)
Guideline revision and electronic health record modification resulted in a 27% reduction in the mean rasburicase dose and a 50% reduction in repeat rasburicase dosing without a negative impact on clinical efficacy.